Novo Nordisk Once-Weekly Insulin Hits Primary Goals In In Two Phase 3 Trials

Novo Nordisk A/S NVO announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec in adults with type 2 diabetes.
In ONWARDS 3 study, after 26 weeks of treatment, hemoglobin A1c, a measure of blood sugar, had fallen 1.57% from a baseline of 8.5% in the insulin icodec cohort, compared to a 1.36% reduction in the control group.
Related: Novo Nordisk's Once-Weekly Insulin Icodec Shows Favorable Reduction In HbA1c In Type 2 Diabetes.
Novo saw no statistically significant difference in severe or clinically significant hypoglycemia, although the rate was numerically higher in the insulin icodec group.
The firm said the drug appeared safe and well tolerated.
In ONWARDS 4 study, after 26 weeks, hemoglobin A1c had fallen 1.16% from a baseline of 8.3% in the insulin icodec cohort, compared to a 1.18% reduction in the control group.
Novo now has data from five of the six phase 3 ONWARDS program trials. Top-line results from the remaining study, ONWARDS 5, are due by the end of the year.
Price Action: NVO shares are down 0.34% at $116.00 during the market session on the last check Friday.

Overview Rating:

Good

0100